Clinical Trials Logo

Clinical Trial Summary

There are limited but encouraging results supporting the use of dalfampridine in patients with hereditary spastic paraplegia. The investigators aimed to investigate the effects of dalfampridine on walking speed, muscle length, spasticity, functional strength, and functional mobility in patients with hereditary spastic paraplegia. In this triple-blinded, randomized, placebo-controlled trial, 4 patients with hereditary spastic paraplegia received dalfampridine (10 mg twice daily) plus physiotherapy (2 times per week), and 4 patients received placebo plus physiotherapy for a total duration of 8 weeks. The assessor and treating physiotherapists, and patients were masked to the group allocation. The primary outcome was Timed 25-foot Walk Test at the end of the 8-week treatment. The secondary outcome measures were functional mobility, functional muscle strength, muscle length, and spasticity.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05613114
Study type Interventional
Source European University of Lefke
Contact
Status Completed
Phase N/A
Start date August 3, 2020
Completion date March 12, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT05373082 - Identification of Modifying Factors in Hereditary Spastic Paraplegia
Recruiting NCT03981276 - Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Terminated NCT02859428 - Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
Completed NCT03104088 - Studying Cognition in SPG4
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Completed NCT02604186 - Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Phase 2/Phase 3
Completed NCT04912609 - Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
Recruiting NCT03206190 - The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 N/A
Completed NCT03627416 - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy N/A
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Withdrawn NCT05411627 - A Pilot Study of Shockwave Therapy in HSP N/A
Completed NCT03961906 - Physiotherapy in Hereditary Spastic Paraplegia Phase 2
Completed NCT05767268 - Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT04180098 - Improving Gait Adaptability in Hereditary Spastic Paraplegia N/A
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Recruiting NCT04712812 - Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Recruiting NCT05354622 - Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders